Predicting Response to Lenalidomide in Myelodysplastic Syndrome
Author Information
Author(s): Ebert Benjamin L, Galili Naomi, Tamayo Pablo, Bosco Jocelyn, Mak Raymond, Pretz Jennifer, Tanguturi Shyam, Ladd-Acosta Christine, Stone Richard, Golub Todd R, Raza Azra
Primary Institution: Broad Institute of Harvard and Massachusetts Institute of Technology
Hypothesis
Can gene expression profiling predict lenalidomide response in myelodysplastic syndrome patients without 5q deletions?
Conclusion
The study found that a specific gene expression signature can predict which myelodysplastic syndrome patients are likely to respond to lenalidomide treatment.
Supporting Evidence
- Gene expression profiling identified a set of genes that predict lenalidomide response.
- The response signature was validated in an independent set of samples.
- Patients with decreased expression of the erythroid differentiation signature were more likely to respond to lenalidomide.
- Lenalidomide treatment promoted erythroid differentiation in vitro.
Takeaway
Researchers figured out a way to tell which patients with a blood disorder will benefit from a medicine called lenalidomide by looking at their genes.
Methodology
Gene expression profiling was used to identify a molecular signature in bone marrow samples from patients with myelodysplastic syndrome.
Limitations
The predictive test needs further validation in larger patient populations before clinical use.
Participant Demographics
Patients with low- or intermediate-1-risk myelodysplastic syndrome, including those with and without 5q deletions.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website